Olaf-oliver Wolz
Tuebingen, BW 72076, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
Journal: Human vaccines & immunotherapeutics
Published: October 18, 2024
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity.
Journal: Vaccines
Published: February 13, 2024
Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189].
Journal: Vaccine: X
Published: May 03, 2023
A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant.
Journal: Vaccines
Published: February 22, 2022
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Journal: Wiener klinische Wochenschrift
Published: July 02, 2021
Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling.
Journal: Frontiers in immunology
Published: October 12, 2020
BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity.
Journal: The Journal of experimental medicine
Published: August 04, 2020
Putative link between Polo-like kinases (PLKs) and Toll-like receptor (TLR) signaling in transformed and primary human immune cells.
Journal: Scientific reports
Published: June 11, 2018
Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.
Journal: Cancer immunology, immunotherapy : CII
Published: May 01, 2018
The fungal ligand chitin directly binds TLR2 and triggers inflammation dependent on oligomer size.
Journal: EMBO reports
Published: March 06, 2018
Last Updated: 09/26/2026